[go: up one dir, main page]

PE20081506A1 - Formulaciones de ansamicina - Google Patents

Formulaciones de ansamicina

Info

Publication number
PE20081506A1
PE20081506A1 PE2007001752A PE2007001752A PE20081506A1 PE 20081506 A1 PE20081506 A1 PE 20081506A1 PE 2007001752 A PE2007001752 A PE 2007001752A PE 2007001752 A PE2007001752 A PE 2007001752A PE 20081506 A1 PE20081506 A1 PE 20081506A1
Authority
PE
Peru
Prior art keywords
inhibidor
ansamycin
formulations
hydroxylidrophylidalization
hydrophyllylidrophalylider
Prior art date
Application number
PE2007001752A
Other languages
English (en)
Inventor
Brian C Austad
Louis Grenier
Edward B Holson
John J Lee
Roger H Pak
James R Porter
James L Wright
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of PE20081506A1 publication Critical patent/PE20081506A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO ANSAMICINA BENZOQUINONA TAL COMO 17-AMINO-GELDANAMICINA (17-AG) O 7-ALILAMINO-17-DEMETOXIGELDANAMICINA (17-AAG) Y UN INHIBIDOR DE LA CRISTALIZACION TAL COMO POLIVINILPIRROLIDONA, HIDROXIPROPILMETILCELULOSA, CICLODEXTRINAS, DEXTRANO, ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA PROTEINA DE CHOQUE TERMICO 90 (Hsp90) Y SON UTILES EN EL TRATAMIENTO DEL CANCER Y/O TRASTORNOS HIPERPROLIFERATIVOS
PE2007001752A 2006-12-12 2007-12-10 Formulaciones de ansamicina PE20081506A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87434906P 2006-12-12 2006-12-12
US91447707P 2007-04-27 2007-04-27
US93991307P 2007-05-24 2007-05-24

Publications (1)

Publication Number Publication Date
PE20081506A1 true PE20081506A1 (es) 2008-12-09

Family

ID=39410222

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001752A PE20081506A1 (es) 2006-12-12 2007-12-10 Formulaciones de ansamicina

Country Status (14)

Country Link
US (3) US7947670B2 (es)
EP (1) EP2126548A2 (es)
JP (1) JP2010512397A (es)
KR (1) KR20090098982A (es)
AR (1) AR064304A1 (es)
AU (1) AU2007332727A1 (es)
BR (1) BRPI0720277A2 (es)
CA (1) CA2672537A1 (es)
CL (1) CL2007003604A1 (es)
MX (1) MX2009006166A (es)
NO (1) NO20092274L (es)
PE (1) PE20081506A1 (es)
TW (1) TW200833666A (es)
WO (1) WO2008073424A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687308B1 (en) * 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
EP1716119B1 (en) 2003-12-23 2013-03-06 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
US8188138B2 (en) * 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
CN101389617A (zh) * 2005-10-31 2009-03-18 詹森药业有限公司 制备哌嗪基和二氮杂环庚烷基苯甲酰胺衍生物的新方法
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
ES2567051T3 (es) * 2006-10-27 2016-04-19 Signal Pharmaceuticals, Llc Formas sólidas que comprenden 4-[9-(3S)-(tetrahidro-furan-3-il)-8-(2,4,6-trifluoro-fenilamino)-9H-purin-2-ilamino]-trans-ciclohexan-1-ol, sus composiciones y sus usos
US8426396B2 (en) * 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
ES2347619B1 (es) * 2008-05-13 2011-09-15 Consejo Superior De Investigaciones Cientificas (Csic) (50%) Procedimiento para diseñar una terapia individual antitumoral basado en la deteccion de los niveles de proteina hsp90, el uso de inhibidores de la proteina hsp90 para la elaboracion de composiciones farmaceuticas, las composiciones asi obtenidas y sus aplicaciones.
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
EP2348845A4 (en) * 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2010319322A1 (en) * 2009-11-13 2012-05-31 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
WO2011133675A1 (en) * 2010-04-21 2011-10-27 Teva Pharmaceutical Industries Ltd. Gabapentin enacarbil compositions
AU2011296033A1 (en) * 2010-09-01 2013-04-04 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-HT2C agonists
US9174973B2 (en) * 2011-09-30 2015-11-03 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
WO2016172573A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
JP2017110205A (ja) * 2015-12-11 2017-06-22 日本合成化学工業株式会社 結晶成長抑制剤
AU2018218326A1 (en) * 2017-02-10 2019-08-22 Altum Pharmaceuticals Inc. Compositions of gallium (III) complexes for oral administration
WO2018200534A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
CN111278808B (zh) * 2017-09-07 2024-04-26 安兹克斯特殊目的有限责任公司 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
GB2581154B (en) 2019-02-05 2022-09-28 Colvistec Ag Amorphous pharmaceutical compositions
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU3225693A (en) 1992-01-06 1993-08-03 Pfizer Inc. Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
AU730216B2 (en) 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US6051607A (en) 1998-07-02 2000-04-18 Micro Therapeutics, Inc. Vascular embolizing compositions comprising ethyl lactate and methods for their use
WO2000003737A2 (en) 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble drugs and methods for their production
US6188221B1 (en) 1998-08-07 2001-02-13 Van De Kop Franz Method and apparatus for transmitting electromagnetic waves and analyzing returns to locate underground fluid deposits
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
DE69924004T2 (de) 1998-12-22 2006-02-09 United States Of America Represented By The Secretary, Department Of Health & Human Services Verabreichungssystem für wasserunlösliche arzneistoffe
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
DE60043163D1 (de) 1999-07-09 2009-11-26 Basf Se Verfahren zur Herstellung von Pigmenten mit verbesserten coloristischen Eigenschaften
SE9904382D0 (sv) * 1999-12-02 1999-12-02 Siemens Elema Ab High Frequency Oscillation Patient Ventilator System
JP2004500358A (ja) 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
GT200100039A (es) 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20050203612A1 (en) 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20040148232A1 (en) * 2001-01-22 2004-07-29 Osamu Fushimi Electronic catalog aggregation apparatus for realizing fast and efficient electronic catalog system
SK15732003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2003006555A (ja) 2001-06-25 2003-01-10 Nova:Kk コンテンツ配信方法、シナリオデータ、記録媒体およびシナリオデータ生成方法
JP4032216B2 (ja) 2001-07-12 2008-01-16 ソニー株式会社 光学多層構造体およびその製造方法、並びに光スイッチング素子および画像表示装置
WO2003013430A2 (en) 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
ATE387198T1 (de) 2001-09-24 2008-03-15 Conforma Therapeutic Corp Verfahren zur herstellung von 17-allyl-amino- geldanamycin (17-aag) und anderer ansamycine
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JP2005530689A (ja) 2002-02-08 2005-10-13 コンフォーマ・セラピューティクス・コーポレイション 改良された薬理学的および生物学的特性を有するアンサマイシン
AU2003277299B2 (en) 2002-04-10 2009-12-10 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
JP2005528390A (ja) 2002-04-10 2005-09-22 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン製剤およびその製造ならびに使用方法
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
EP1716119B1 (en) 2003-12-23 2013-03-06 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
CA2551254A1 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
AU2005228886A1 (en) 2004-03-26 2005-10-13 Michigan State University Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
US20050256097A1 (en) 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
WO2005112587A2 (en) 2004-05-12 2005-12-01 Medivas, Llc Wound healing polymer compositions and methods for use thereof
US7179708B2 (en) * 2004-07-14 2007-02-20 Chung Yuan Christian University Process for fabricating non-volatile memory by tilt-angle ion implantation
US20080171687A1 (en) 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
WO2006050457A2 (en) * 2004-11-02 2006-05-11 Conforma Therapeutics Corporation Methods and compositions for treating chronic lymphocytic leukemia
WO2006089207A2 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
CA2596867A1 (en) 2005-02-28 2006-09-08 Kosan Biosciences Incorporated Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
EP1863769A4 (en) 2005-03-11 2009-03-18 Univ Colorado HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
US20060228405A1 (en) 2005-04-07 2006-10-12 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
US20060252740A1 (en) 2005-04-29 2006-11-09 Johnson Robert G Jr Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
AU2006242540A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either
WO2007002093A2 (en) 2005-06-21 2007-01-04 Infinity Discovery, Inc. Ansamycin formulations and methods of use thereof
US7776849B2 (en) 2005-06-29 2010-08-17 Kyowa Hakko Kirin Co., Ltd. Benzenoid ansamycin derivative
US20070026072A1 (en) 2005-07-28 2007-02-01 Stephen Olsen Benzoquinones of enhanced bioavailability
WO2007059116A2 (en) 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US20090042847A1 (en) 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
AU2006320435A1 (en) 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
US20070167422A1 (en) 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin

Also Published As

Publication number Publication date
US20080221077A1 (en) 2008-09-11
CA2672537A1 (en) 2008-06-19
US20090062528A1 (en) 2009-03-05
KR20090098982A (ko) 2009-09-18
EP2126548A2 (en) 2009-12-02
WO2008073424A9 (en) 2008-10-02
US7947670B2 (en) 2011-05-24
AR064304A1 (es) 2009-03-25
TW200833666A (en) 2008-08-16
BRPI0720277A2 (pt) 2014-01-28
MX2009006166A (es) 2009-08-26
US8357676B2 (en) 2013-01-22
JP2010512397A (ja) 2010-04-22
WO2008073424A3 (en) 2008-07-31
WO2008073424A2 (en) 2008-06-19
US8283343B2 (en) 2012-10-09
US20090069281A1 (en) 2009-03-12
NO20092274L (no) 2009-08-25
AU2007332727A1 (en) 2008-06-19
CL2007003604A1 (es) 2009-01-23

Similar Documents

Publication Publication Date Title
PE20081506A1 (es) Formulaciones de ansamicina
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA201170703A1 (ru) Производные адамантилбензамида
PL381247A1 (pl) Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
ATE433447T1 (de) Pyrimiidinverbindungen
MX2009007345A (es) Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo.
PA8548401A1 (es) Agentes antibacterianos
ECSP088429A (es) Diarilureas para el tratamiento de la hipertensión pulmonar
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
NO20082298L (no) Kaliumkanalinhibitorer
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
TW200800967A (en) Benzimidazole thiophene compounds
TW200738659A (en) Novel compounds
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis

Legal Events

Date Code Title Description
FC Refusal